Novartis(NVS)
Search documents
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
GlobeNewswire News Room· 2024-11-25 06:15
Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers Basel, November 25, 2024 – Novartis will present data from m ...
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
ZACKS· 2024-11-22 19:41
Novartis (NVS) announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%.The rise in guidance was due to the strong momentum of NVS’ key drugs and its upcoming launches.Shares of Novartis have risen 4% year to date compared with the industry’s growth of 4.8%.Image Source: Zacks Investment ResearchNVS Raises Mid-Term OutlookFor 2024-2029, sales are ex ...
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
GlobeNewswire News Room· 2024-11-21 06:00
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ peak sales potential and 15+ near-term submission-enabling readouts 30+ high-value medicines in the pipeline expected to support continued mid-single digit sales growth beyond 2029 Basel, November 21, 2024 – Today Novartis announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management ev ...
Novartis ranks first in 2024 Access to Medicine Index
GlobeNewswire News Room· 2024-11-19 13:00
The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industry Novartis has risen three places to secure the top spot on the 2024 Access to Medicine Index Basel, November 19, 2024 – Novartis has ranked first in the ...
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Prnewswire· 2024-11-18 13:00
Ratio to receive upfront, and potential milestones and tiered royalty paymentsBOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and develop ...
Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
ZACKS· 2024-11-14 15:35
A downtrend has been apparent in Novartis (NVS) lately with too much selling pressure. The stock has declined 10.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for s ...
Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
ZACKS· 2024-11-13 15:55
The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts ...
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
ZACKS· 2024-11-13 15:36
Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...
Is Novartis (NVS) Stock Undervalued Right Now?
ZACKS· 2024-11-05 15:45
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by th ...
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Benzinga· 2024-10-30 19:12
On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Guidance: Novartis also raised its 2024 full-year guidance again this year. In a statement, Novartis said it expects full-year core operating income to grow by a "high teens" percentage, compared with previous guidance of a "mid-to-high teens" percentage. Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-s ...